Gallagher & Kennedy, P.A., a full service business law firm, today announced that Mark C. Dangerfield has rejoined the firm as shareholder in the Litigation Department. Mr. Dangerfield practices in the areas of commercial and appellate litigation, including business torts and contracts, professional malpractice, securities and real estate.
Mr. Dangerfield left Gallagher & Kennedy in 2010 to assist Brigham Young University, his undergraduate alma mater, in high-stakes litigation against Pfizer Pharmaceuticals involving the blockbuster arthritis drug Celebrex. The case received national attention and was amicably settled in 2012.
In addition to his experience handling trials and pre-trial litigation, Mr. Dangerfield has managed Arizona appeals on many issues resulting in reported decisions and favorable settlements. Mr. Dangerfield is a member of the State Bar of Arizona, the U.S. Supreme Court and the U.S. Court of Appeals in the Fourth, Fifth, Eighth, Ninth and Tenth Circuit Courts. He is listed in the Martindale-Hubbell® AV Peer Review Rating and in Best Lawyers, commercial litigation.
Mr. Dangerfield earned his J.D. in 1986 from Harvard University and his B.A., magna cum laude, in 1975 from Brigham Young University. In his free time, he enjoys running marathons and ultra-marathons and has completed more than 60 marathons in 37 states and on all of the seven continents.